马汉九里香碱
中文名称 | 马汉九里香碱 |
---|---|
中文同义词 | (+)-3,11-二氢-3,5-二甲基-3-(4-甲基-3-戊烯-1-基)吡喃并[3,2-A]咔唑;马汉九里香碱;月桔宾;化合物 T15949 |
英文名称 | Mahanimbine |
英文同义词 | Mahanimbine;Mahanimbin;(+)-3,11-Dihydro-3,5-dimethyl-3-(4-methyl-3-penten-1-yl)pyrano[3,2-a]carbazole;Pyrano[3,2-a]carbazole, 3,11-dihydro-3,5-dimethyl-3-(4-methyl-3-penten-1-yl)-, (3S)-;(+)-Mahanimbine;Mahanimbine-RM |
CAS号 | 21104-28-9 |
分子式 | C23H25NO |
分子量 | 331.45 |
EINECS号 | |
相关类别 | 中药对照品;生物碱 |
Mol文件 | 21104-28-9.mol |
结构式 |
马汉九里香碱 性质
熔点 | 94-95 °C |
---|---|
沸点 | 502.6±39.0 °C(Predicted) |
密度 | 1.109 |
溶解度 | 二甲基亚砜:10mM |
酸度系数(pKa) | 17.31±0.40(Predicted) |
稳定性 | 感光 |
Mahanimbine (2-4 mg/kg; p.o.; daily for 12 weeks) prevents HFD-induced weight gain in mice (male and female).
Mahanimbine prevented HFD-induced hyperlipidemia and fat accumulation in adipose tissue and liver along with the restricted progression of systemic inflammation and oxidative stress.
Mahanimbine treatment improves glucose clearance and upregulates the expression of insulin responsive genes in liver and adipose tissue.
Animal Model: | Swiss albino mice (7-8 weeks old, both sex) |
Dosage: | HFD+LD (2 mg/kg of body weight of mahanimbine), HFD+HD (4 mg/kg of body weight of mahanimbine); |
Administration: | Oral suspension; daily for 12 weeks |
Result: | Male HFD+LD and HFD+HD groups showed 51.70±6 3.59% and 47.37±3.73% weight gain, respectively, as compared with 71.02±6 6.04% in HFD fed mice whereas female HFD+LD and HFD+HD groups showed 24.31±1.68% and 25.10±2.61% weight gain as compared with HFD group with 36.69±3.60% of weight gain. |
安全信息
危险类别码 | 53 |
---|---|
WGK Germany | 3 |
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/11/08 | HY-124557 | 马汉九里香碱 Mahanimbine | 21104-28-9 | 1mg | 11750元 |
2023/03/20 | HY-124557 | 马汉九里香碱 Mahanimbine | 21104-28-9 | 5mg | 8200元 |